Login to Your Account



Pharma: Clinic Roundup


Tuesday, December 4, 2012
• Upsher-Smith Laboratories Inc., of San Diego, said Phase I data showing that USL261 (intranasal midazolam) demonstrated that maximum midazolam plasma concentrations were rapidly achieved after dosing, and both midazolam and its metabolite were rapidly eliminated.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription